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Abstract
Background-Hepatocellular carcinoma
(HCC) is one ofthe most common cancers
in the world. The geographical prevalence
varies considerably in different countries
and Scotland is regarded as an area oflow
risk for the disease.
Aims-To assess the association between
chronic hepatitis C infection (HCV) and
HCC in a population of patients pre-
senting to a single hospital.
Patients-One hundred and fourteen
cases of histologically confirmed liver
cancer presenting to the Royal Infirmary
of Edinburgh between 1985 and 1994 were
examined.
Methods-Of 114 cases of HCC, 80
samples of stored sera were available.
Samples positive for HCV Ab were geno-
typed by restriction fragment length
polymorphism analysis ofHCV c-DNA. A
population of 29 cirrhotic patients (diag-
nosed between 1985 and 1994) with chronic
HCV infection was also genotyped.
Results-Chronic HCV infection was a
major risk factor (30% of tested HCC
patients) identified. HCV genotype lb was
predominant (16 of 20 patients). The time
fromHCV transmission to development of
cancer ranged from 10 to 50 years (median
30). In the cirrhotic patient population, a
broader distribution of genotypes was
present (genotype la: 7; genotype lb: 8;
genotype 2b: 3; genotype 3a: 8 and
genotype 4: 2). However, this population
was significantly younger. (Mean (SD) 52
(14.5) years) (p=0.0002) and demonstrated
a significantly shorter duration of in-
fection: range 10-40 years (median: 19).
Conclusion-There is a strong association
between chronic HCV infection, cirrhosis,
and hepatocarcinogenesis in this Scottish
population. The study was unable to
distinguish whether the high prevalence of
genotype lb in the HCC population
reflected increased oncogenicity in itself,
or whether lb was simply the most
prevalent genotype in Scotland when these
patients were infected.
(Gut 1997; 40: 128-132)
Keywords: hepatocellular carcinoma, hepatitis C virus,
HCV genotypes, hepatitis B virus.
Hepatocellular carcinoma (HCC) is one of the
most common cancers in the world, with an
estimated annual incidence of 500 000 to
1 000 000 new cases.' Geographical areas carry
different risk factors; the United Kingdom is
regarded as an area of low risk of developing
the disease.2 It has been known for many years
that hepatitis B virus (HBV) infection, afla-
toxin B 1 exposure, consumption of excess
alcohol, and some hereditary conditions
(haemochromatosis, xl antitrypsin deficiency,
and hereditary tyrosinaemia) are important risk
factors. Recently, there has been renewed
interest in primary liver cancer, following the
recognition of the importance of chronic
hepatitis C infection (HCV); epidemiological
surveys have identified HCV in between
15-80% of patients with HCC depending on
the population studied.3 HCV seems to be the
major cause ofHCC in Japan, Italy, and Spain,
but is less important in South Africa and
Taiwan.'2 There are no published data
relating to HCV associated HCC in the United
Kingdom.
Examination of the epidemiology of HCV
infection in different geographical regions and
in different age, risk, and racial groups has
become possible following the identification
and classification of viral genotypes. 3 The viral
genome is divided into a structural and non-
structural region. The structural region
contains genes for a nucleocapsid protein and
the envelope glycoproteins. The genes in the
non-structural region code for functional
proteins. In addition, a nuceleotide sequence at
the 5' portion in the structural region does not
encode a gene product. This 5' non-coding
(5'-NCR) sequence is the most highly con-
served region; the greatest heterogeneity
occurs in the envelope proteins. HCV has been
classified into a total of six major genotypes,
showing not more than 70% sequence
homology, by the distinct nucleotide sequences
in the 5'-NCR; many of these contain a
number of more closely related subgroups (a,
b, and c).'4 Viruses may be typed by restriction
fragment length polymorphism (RFLP)
analysis of cDNA amplified from the 5'-NCR
by the reverse transcription polymerase chain
reaction (RT-PCR).'5 Preliminary reports
suggest major biological differences between
the genotypes in response to treatment with
interferon'6-8 and perhaps, progression and
severity of disease.'9
In this study, we aimed to assess the
association between chronic HCV infection
and HCC over a 10 year period, in cases
presenting to a single hospital in Scotland.
Modes of transmission of HCV, incubation of
infection, and cofactors in the development of
primary liver cancer were also considered.
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Methods
Patients
A total of 114 cases of histologically confirmed
hepatocellular carcinoma (mean (SD) age:
69-2 (11-4) years; 90 male; 109 (950/o) of
whom were ethnically Scottish), presenting
to the Royal Infirmary, Edinburgh between
1 January 1985 and 31 December 1994 were
included. The cases were obtained from exam-
ination of biopsy and necropsy data (stored in
the University of Edinburgh Pathology
Department) and also International Classifi-
cation of Diseases hospital admissions data.
The records of these patients were examined
to identify the aetiology of HCC. Docu-
mentation of the histology of liver tissue
surrounding the cancer, together with possible
sources of transmission and duration of blood
borne infectious hepatitis was made. The time
of transmission of HCV infection was cal-
culated from the year of first intravenous drug
abuse or first blood transfusion; only these
patients were used to calculate the range/
median duration of infection. Serum samples
had been stored at -70°C, from the time of
diagnosis ofHCC.
Serological markers of HBV infection were
detected with standard assays (RIA, Abbott
laboratories, Weisbaden, Germany).
Anti-HCV antibodies were detected by a
second generation enzyme immunoassay (EIA,
Abbot laboratories, Weisbaden, Germany) and
also by third generation recombinant immuno-
blot assays (RIBA-3, Chiron, Emeryville, CA)
for antibody to non-structural proteins 5-1-1
(NS4), c-100-3 (NS4), c33c (NS3), and core-
associated antigen c-22-3.
A population of cirrhotic patients (n=29; 22
male; mean (SD) age: 52 (14-5) years),
presenting during the same time period
(1985-1994), was also examined. All had
chronic hepatitis C infection; a significant
proportion had previously been diagnosed as
having 'cryptogenic' cirrhosis.
RNA extraction
Viral RNA was extracted from 0 5 ml of stored
serum from each of the patients as previously
described.20 Briefly, serum samples were incu-
bated at 37°C for 1 5 hours with 1 mg/ml
proteinase K in the presence of 40 ,ug/ml
polyadenylic acid, 0-5% SDS, 0- 1 M NaCl, 50
mM TRIS HCL (pH 8 0), and 1 mM EDTA.
Nucleic acid was extracted successively with
phenol and chloroform-isoamyl alcohol (50:1)
and precipitated by the addition of one tenth
volume of sodium acetate (pH 5 2) and two
volumes of ethanol. The dried pellet was re-
suspended in 25 pAl of diethyl pyrocarbonate
treated water.
HCVgenotyping
RNA was reverse transcribed and amplified
using nested primers matching conserved
regions in the 5'-NCR." Product DNAs were
cleaved with restriction enzymes Hae-1 1 /Rsa-
1 and Mva-l/Hinf-1.22 The fragments were
separated by agarose gel electrophoresis using
4% metaphor agarose (FMC BioProducts,
Rockland, ME). Phylogenetic comparisons of
sequences in the conserved region of the
genome confirm that the 5'-NCR can be used
to distinguish the six major genotypes of
HCV.23 Separation of subtypes la and lb was
undertaken by the cleavage patterns resulting
from digestion with Mvn-l.20 In three cases
direct nucleotide sequencing of PCR products
was carried out.
Results
Of 114 patients with HCC, presenting to the
Royal Infirmary, Edinburgh over a 10 year
period, 80 (70%) stored serum samples were
available for HCV testing and assessment of
HCC aetiology.
Aetiology ofHCC
HCV Ab serology was positive in 24 (21 male;
mean (SD) age: 67 (12) years; all ethnically
Scottish) cases (30% of tested samples); of
whom two also had markers of current HBV
infection (HBsAg positive), and a further six
had markers of past infection (HBsAg negative;
anti-HBs positive; anti-HBc positive). An
additional two had a history of alcohol abuse
(>40 units/week) for more than 10 years.
Twenty of 24 cases were positive for HCV
RNA by RT-PCR.
Examination of cases with negative HCV
serology indicated that 13 (16%) were chronic
carriers of the HBV virus (HBsAg positive);
alcohol misuse was the sole risk factor in 16
(20%) cases; haemochromatosis in seven (9%);
primary biliary cirrhosis in two (2.5%), and
acute intermittent porphyria in two (2/5%). In
16 (20%) cases, the aetiology of liver cancer
could not be determined either from the
medical records or from serology (Fig 1).
HCVgenotyping in HCC and cirrhotic
populations
Genotyping of the virus was possible in 20 of
24 patients; it was lb in 16; genotype 4 in
three, and genotype 5 in one. In the cirrhotic
population, a broader genotype distribution
was demonstrated: genotype la: n=7; genotype
lb: n=8; genotype 2b: n=3; genotype 3a: n=8,
and genotype 4: n=2. One cirrhotic patient was
serum HCV RNA negative by RT-PCR
(Table).
Risk factors forHCVtransmission and duration
of infection
Examination of risk factors for HCV trans-
mission identified 15 patients who had had
blood transfusions between 1940 and 1972 in
Scotland; two of these had had more than one
transfusion. One, had current infection with
HCV, HBV, and HIV at diagnosis following
injection of intravenous drugs between 1979
and 1989. A further eight patients (one of
whom was a Jehovah's Witness) had no recog-
nised risk factors for HCV infection. There
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Figure 1: Aetiology of hepatocellular carcinoma (diagnosed between 1985 and 1994) in the
80 patients in whom stored samples of sera were available for anti-HCV testing. The bars
are stacked to illustrate the background histology of the patients.
were no data availabe concerning the
acquisition of HCV infection by covert percu-
taneous exposure of non-parenteral routes.
The time from presumed HCV transmission to
development of HCC ranged from 10 to 50
years (median 30) in the post-transfusion/
intravenous drug misuse patients.
The range in duration of infection in the
cirrhotic population was 10 to 40 years
(median 19); this was a significantly shorter
duration than in the HCC population
(p=O OOO9).
Histology of non-cancerous liver tissue in the
HCC population
Cirrhosis preceded HCC in 20 of 24 HCV
infected cases (83%). In two cases, HCC
developed from a hepatitic liver, and in one
(the patient had a lobectomy), the background
histology of the tumour was normal (Fig 2).
In the whole HCC population, cirrhosis
preceded HCC in 66 (82-/5%) cases; other
pathology was demonstrated in eight (10%),
and it was unclassified (because the tumour
alone was biopsied) in six (7 5%).
Discussion
In this study, we have identified chronic HCV
infection as a major risk factor for the
development of HCC in a Scottish population,
a finding already made in high risk aeras of
HCC, such as Japan, Italy, and Spain.4
There is a strong association between
chronic HCV infection and hepatocarcino-
genesis, through the pathway of chronic liver
injury, regeneration, and cirrhosis; cirrhosis
preceded HCC in 20 of 24 (83%) of our cases
(Fig 2). In Western countries, the cancer
commonly occurs late in life, mostly in
cirrhotic nodules.24 25 Our study supports this
finding; the patients were elderly and most
were infected after receiving blood transfusions
a median time of 30 years previously. This is
a similar time period to that noted in a recent
study from Spain, which found the interval
between the date of blood transfusion and the
diagnosis of HCC to be 26-8 (12-4) years.20
However, in three of our cases, a tumour
developed from a normal or hepatitic liver;
further evidence for the persistence and
replication of HCV genomes in primary liver
cancer developing in the absence of cirrhosis or
other risk factors.27 In these cases, the mode of
hepatocarcinogenesis is unclear; HCV lacks
reverse transcriptase activity and is not thought
to be associated with genomic integration,
while little is known about the biological
properties of HCV proteins. Certainly, the
mechanism is different to hepatitis B virus
(HBV). HBV is believed to be directly onco-
genic either by HBV integration causing
increased genomic instability or by trans-
activation of cellular genes.28 30
Cofactors to HCV seropositivity in the
development of HCC were noted in four
patients; either current HBV infection (two
patients) or alcohol misuse (two patients). A
further six patients had markers of past hepa-
titis B infection (HBsAg negative; anti-HBs,
and anti-HBc positive). HBV may still be impli-
cated in these cancers because its DNA can
persist in both serum and liver of patients with
serology of past infection.3' 32 The relation
Comparison between HCV associated HCC population and HCV associated cirrhotic population
HCV asssociated HCC HCV associated cirrhosis Significance
Number 24 29
Age (y)* 67 (12) 52 (14-5) p=0 0002
Sex (M:F) 21:3 22:7
Years of diagnosis 1986-1995 1986-1995
Mode of infection RCC Transfusion: 15 RCC Transfussion: 9
IVDA: 1 IVDA: 11
Sporadic: 8 Haemophiliac: 3
Sporadic: 6
Duration of infection (Y)t 30 (10-50) 19 (10-40) p=0 0009
Alcohol misuse 2 9
Current HBV infection 2 1
Past HBV infection 6 9
Serum RT-PCR positive (HCV RNA) 20 28
HCV genotypes (0) Genotype lb: 16 (80) Genotype la: 7 (25)
Genotype 4: 3 (15) Genotype lb: 8 (29)
Genotype 5: 1 (5) Genotype 2b: 3 (10)
Genotype 3a: 8 (29)
Genotype 4: 2 (7)
(*mean (SD); tmedian (range)). In the cirrhotic population a wider distribution of genotypes was noted; however, this population
was significantly younger and had a significantly shorter duration of HCV infection than the HCC population.
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Figure 2: Histology ofnon-cancerous liver tissue. The background liver histology of the
patients with positive anti-HCVserology is shown. The majority were cirrhotic (80%).
between the two viruses is unclear. In vitro,
HCV core protein can suppress HBV expres-
sion and encapsulation33; while clinical studies
have suggested a reciprocal and inverse relation
between HCV and HBV replication.34 Further
studies are required to determine whether there
is synergy between the HCV genome and HBV
DNA in the process of hepatic oncogenesis.
HCV genotype lb was predominant (16 of
20 patients: 80%); this genotype has previously
been reported to be responsible for the develop-
ment of severe liver disease and the failure of
interferon therapy.18 19 35 36 The dominance of
this type contrasts both with the genotype
distribution in current Scottish blood donors,
(where type la forms the majority: 70-80%),"4
and in our population of cirrhotic patients (only
eight of 28 patients were infected with genotype
lb: 28%). The difference in epidemiology may
be partly explained by the prevalence of type lb
in older patients and in those with a longer
duration of infection (our HCC population was
significantly older, and had been infected signi-
ficantly longer than the cirrhotic population).
The distribution of HCV genotypes among
blood donors in Scotland 30 to 50 years ago is
unknown; identification of patients who
received blood transfusions containing
genotypes other than lb, and their clinical
course, would provide a control group to the
patients who developed cancer in this study.
Unfortunately, it is not possible to identify
these patients and the suspicion remains that
the prevalence of genotype lb in this HCC
population represents the most prevalent
genotype a median time of 30 years ago.
Genotype 4 is commonly associated with
HCV infection in Egypt, other African
countries, and the Middle East.37 It has not
been reported in Scottish or European blood
donor populations The six patients with
genotype 4 and HCC had not visited any of
these countries; however, all six were infected
through blood transfusions in the 1940s and
1 960s. Likewise, genotype 5 was also asso-
ciated with HCC in one case, where a patient
had received a blood transfusion in 1966, but
had never travelled to the African continent.
This genotype was originally found in South
Africa; low frequencies have been reported in
the Netherlands, Australia, and Canada.37
Currently, this is the only evidence for the
association of genotypes 4/5 and primary liver
cancer in the Western world.
In conclusion, these findings indicate that, in
a population of Scottish patients, there is a
strong association between chronic HCV
infection, cirrhosis, and hepatocarcinogenesis.
However, the study was unable to distinguish
whether the high prevalence of genotype lb in
the HCC population reflects increased onco-
genicity in itself, or simply a background epi-
demiology of the most prevalent genotype, a
median time of 30 years ago. Larger, popu-
lation based studies are required to confirm
that HCV genotypes vary in their propensity to
produce clinically significant liver disease; and
to establish the role of cofactors and the host
response in these processes.
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